8-K: Veradigm Provides Financial Updates for 2023, 2024, and Outlook for 2025; Files Restated 2022 Form 10-K

Veradigm announces updated financial estimates for 2023 and 2024, provides an outlook for 2025, and reports the filing of its restated 2022 Form 10-K.

Summary

• Veradigm has released updated financial information for fiscal years 2023 and 2024, along with its outlook for 2025.
• The company filed its comprehensive Annual Report on Form 10-K for the year ended December 31, 2022, which includes restated financial statements for 2020, 2021, and 2022.
• For 2023, Veradigm estimates GAAP revenue between $620 million and $625 million, including $19 million from favorable customer settlements.
• GAAP Net Income for 2023 is estimated between $62 million and $65 million, with an Adjusted EBITDA between $139 million and $144 million.
• Net Cash as of December 31, 2023, was $239 million, comprising $447 million in cash and cash equivalents and $208 million in debt from convertible notes.
• For 2024, Veradigm estimates GAAP revenue between $583 million and $588 million, including $1 million from favorable customer settlements.
• GAAP Net Loss for 2024 is estimated between $49 million and $46 million, with an Adjusted EBITDA between $85 million and $90 million.
• Net Cash as of December 31, 2024, was $87 million, including $295 million in cash and cash equivalents and $208 million in debt.
• The company expects 2025 GAAP revenue to be approximately flat compared to 2024, and Net Cash is expected to remain positive.
• Veradigm management plans to host an investor conference call and webcast on March 19, 2025, to discuss the updates.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company expresses confidence and is taking steps to address its issues, the financial results show a decline in performance and ongoing challenges with financial reporting.

Positives

• Veradigm's management expresses confidence in its business model and value proposition.
• The company is focused on remediating material weaknesses and internal control deficiencies.
• Veradigm is committed to becoming current in its financial reporting and relisting its common stock.
• The company reported net cash of $239 million as of December 31, 2023.
• The company reported net cash of $87 million as of December 31, 2024.
• The filing of the 2022 Form 10-K represents an important step toward regaining compliance with financial reporting obligations.

Negatives

• Veradigm experienced a GAAP Net Loss estimated between $49 million and $46 million for 2024.
• Cash decreased approximately $152 million from 2023 levels, reflecting outflows for acquisitions, capital expenditures, and transaction expenses.
• The company acknowledges material weaknesses and internal control deficiencies that need remediation.
• The company's common stock is not trading on a national securities exchange.

Risks

• The preliminary financial results for 2023 and 2024 are subject to change and have not been audited.
• The company faces risks related to its common stock not trading on a national securities exchange and deregistration from Section 12(b) of the Securities Exchange Act of 1934.
• There is a risk of further material delays in financial reporting or the ability to hold an annual meeting of stockholders.
• The company may face challenges in timely preparing its delinquent financial statements.
• Reviews and investigations could identify additional errors and material weaknesses in accounting practices.
• The company is subject to a putative securities class action lawsuit and a stockholder derivative action.
• The company's ability to enter into a new financing arrangement on acceptable terms is uncertain.
• Integrating the operations of ScienceIO may present challenges, risks, and costs.

Future Outlook

Veradigm expects 2025 GAAP revenue to be approximately flat compared to 2024, and Net Cash is expected to remain positive.

Management Comments

• Tom Langan, Interim Chief Executive Officer, stated, 'We remain confident in Veradigms business model and our value proposition.'
• Tom Langan, Interim Chief Executive Officer, stated, 'We remain focused on remediating our material weaknesses and other internal control deficiencies, becoming current in our financial reporting, executing against our growth strategy to deliver end-to-end solutions for our clients, and relisting our common stock.'
• Lee Westerfield, Interim Chief Financial Officer, stated, 'We are pleased to have filed the 2022 Form 10-K as part of a comprehensive undertaking that involved a detailed and thorough examination of our financial statements, as well as our accounting policies and processes.'

Industry Context

Veradigm, as a healthcare technology company, operates in a competitive market where data and technology solutions are increasingly vital for providers, payers, and biopharma companies. The company's focus on remediating internal control deficiencies and relisting its stock suggests an effort to regain investor confidence and maintain competitiveness.

Comparison to Industry Standards

• It's difficult to directly compare Veradigm's performance without knowing specific growth rates and profitability metrics of its direct competitors.
• Companies like Cerner (now Oracle Health), Epic Systems, and Allscripts are major players in the healthcare technology space.
• Veradigm's revenue decline in 2024 and net loss raise concerns compared to industry leaders who often demonstrate consistent growth and profitability.
• The restatement of financial statements and internal control issues are significant deviations from industry best practices and require thorough remediation to align with standards set by companies like McKesson and UnitedHealth Group's Optum.

Legal Proceedings

• The company is subject to a putative securities class action lawsuit and a stockholder derivative action.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial performance, delayed reporting, and ongoing litigation.
• Employees may be affected by the company's restructuring and remediation efforts.
• Customers could experience disruptions if the company's financial challenges impact its ability to deliver services.
• Creditors face increased risk due to the company's net loss and declining cash position.

Next Steps

• Veradigm plans to host an investor conference call and webcast on March 19, 2025.
• The company will continue to focus on remediating material weaknesses and internal control deficiencies.
• Veradigm aims to become current in its financial reporting and relist its common stock.

Key Dates